Equities

Innovita Biological Technology Co Ltd

688253:SHH

Innovita Biological Technology Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)36.96
  • Today's Change-6.04 / -14.05%
  • Shares traded965.03k
  • 1 Year change+53.23%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,6971,503567
Total Receivables, Net1071364.66
Total Inventory627544
Prepaid expenses7.102433
Other current assets, total------
Total current assets1,8731,738648
Property, plant & equipment, net130169129
Goodwill, net------
Intangibles, net7.027.257.49
Long term investments34155.00
Note receivable - long term------
Other long term assets------
Total assets2,0661,943798
LIABILITIES
Accounts payable646921
Accrued expenses273820
Notes payable/short-term debt0200
Current portion long-term debt/capital leases1.963.010.88
Other current liabilities, total1221139.90
Total current liabilities21524352
Total long term debt1.042.490.52
Total debt3.00251.40
Deferred income tax2.581.310.05
Minority interest000
Other liabilities, total4.806.336.99
Total liabilities22425360
SHAREHOLDERS EQUITY
Common stock136136102
Additional paid-in capital1,0241,022256
Retained earnings (accumulated deficit)683531380
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(1.02)----
Total equity1,8421,689738
Total liabilities & shareholders' equity2,0661,943798
Total common shares outstanding136136136
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.